Cargando…
Cholesterol Metabolism as a Potential Therapeutic Target and a Prognostic Biomarker for Cancer Immunotherapy
Checkpoint-based immunotherapies, such as programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors, have shown promising clinical outcomes in many types of cancers. Unfortunately, the response rate of immune checkpoint inhibitors is low. It is very important to discover novel...
Autores principales: | Zhang, Huixian, Zhao, Wencheng, Li, Xingya, He, Yayi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232957/ https://www.ncbi.nlm.nih.gov/pubmed/34188488 http://dx.doi.org/10.2147/OTT.S315998 |
Ejemplares similares
-
Cholesterol Metabolism: A Potential Therapeutic Target in Glioblastoma
por: Ahmad, Fahim, et al.
Publicado: (2019) -
Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy
por: Jiang, Minlin, et al.
Publicado: (2021) -
Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy
por: Amor, Fatima, et al.
Publicado: (2021) -
TIM-3, a promising target for cancer immunotherapy
por: He, Yayi, et al.
Publicado: (2018) -
DHX37 Is a Promising Prognostic Biomarker and a Therapeutic Target for Immunotherapy and Chemotherapy in HCC
por: Liu, Nanbin, et al.
Publicado: (2023)